Anagrelide Dosage

This dosage information may not include all the information needed to use Anagrelide safely and effectively. See additional information for Anagrelide.

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Thrombocythemia

Initial: 0.5 mg orally 4 times a day, or 1 mg orally twice a day, for a minimum of 7 days.

Maintenance: titrate to the lowest effective dosage required to reduce and maintain the platelet count at less than 600,000 cells/microliter, ideally down to normal levels. Increase the dosage by no more than 0.5 mg/day in any 1 week period.

The dosage should not exceed 10 mg/day or 2.5 mg in any single dose.

Usual Pediatric Dose for Chronic Myelogenous Leukemia

Study (n=12)
0.5 mg four times daily, to a maximum daily dose of 10 mg.

Usual Pediatric Dose for Thrombocythemia

Study (n=12)
0.5 mg four times daily, to a maximum daily dose of 10 mg.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Use of anagrelide in patients with severe hepatic impairment is contraindicated. Patients with moderate hepatic impairment should receive a starting dose of 0.5 mg/day and be maintained at that dose for a minimum of one week (careful monitoring of cardiovascular effects should be instituted during this time). Incremental increases should not exceed more than 0.5 mg/day in any one-week.

Dose Adjustments

Most patients will experience an adequate response at a dose of 1.5 to 3 mg/day.

Typically, platelet count begins to respond within 7 to 14 days at the proper dosage.


Platelet count should be monitored every 2 days during the first week of treatment and at least weekly thereafter until the maintenance dosage is established, to prevent the occurrence of thrombocytopenia.

While the platelet count is being lowered (during the first two weeks of treatment), closely monitor blood counts (hemoglobin, white blood cells), liver function (SGOT, SGPT) and renal function (serum creatinine, BUN).

Many of the side effects attributable to anagrelide involve the cardiovascular system and may be a direct result of the drug's positive inotropic properties. Vasodilation, tachycardia, palpitations, and congestive heart failure may occur with the use of anagrelide, therefore, obtaining baseline and follow-up cardiovascular parameters are vital parts of successful treatment.

An increase in the platelet count can be seen within four days after sudden stoppage of anagrelide.


Data not available